40 results about "Pulmonary Macrophages" patented technology

The invention relates to polypeptide gold nanoparticles modified by trace cigarette extract CSE (0.1%-1%) and application of the polypeptide gold nanoparticles in preparation of drugs for treating chronic obstructive pulmonary diseases. The polypeptide-modified gold nanoparticle is a polypeptide-modified gold nanoparticle as shown in a sequence SEQ ID NO: 1. It is confirmed for the first time that polypeptide (CLPFFD, SEQ ID NO: 1) gold nanoparticles modified by trace CSE (0.1%-1%) can antagonize mtDNA synthesis and inhibit mitochondrial ROS generation so as to inhibit activation of macrophage NLRP3 inflammasome, induce depolarization of macrophage and target lung macrophage in vivo to achieve anti-inflammatory activity, and the polypeptide (CLPFFD, SEQ ID NO: 1) gold nanoparticles can be used for preparing anti-inflammatory drugs. The compound has an obvious treatment effect in a COPD acute exacerbation model and a stable phase model, so that the compound can be used for preparing medicines for treating COPD. The medicine has the advantages of being remarkable in curative effect, capable of acting on specific cells in a targeted mode, convenient to track in vivo and the like, and a new treatment means is provided for COPD.

The invention discloses an alveolar macrophage glycyrrhetinic acid liposome and a preparation method thereof, and belongs to the field of biological medicines. The surface of glycyrrhetinic acid lipidosome is modified with alveolar macrophage targeting molecules, so that the lipidosome can specifically target M1 alveolar macrophages induced by lipopolysaccharide serving as a main component of the outer wall of gram-negative bacteria, entrapped glycyrrhetinic acid is ingested by the alveolar macrophages, M2 polarization is specifically induced, and the specific targeting effect is achieved. Lung inflammatory injury caused by gram-negative bacteria is reduced, lung tissue injury and fibrosis caused by excessive inflammation are prevented, and great significance is achieved for pneumonia caused by gram-negative bacteria.

The invention belongs to the field of traditional Chinese medicines, and particularly relates to an inhalation type pharmaceutical composition for treating inflammatory respiratory diseases and a preparation method thereof. The inhalation type pharmaceutical composition comprises an active component and a nano-liposome, and mannose is modified on the surface of the nano-liposome; the active ingredients comprise bulbus fritillariae cirrhosae total alkaloids and platycodin D; the nano-liposome is prepared from the following raw materials: phospholipid, cholesterol and cholesterol-polyethylene glycol 1000-mannose ester. The liposome can be specifically recognized by a mannose receptor highly expressed on the surface of alveolar macrophage through a surface-modified mannose ligand, so that the receptor-mediated endocytosis is started, and the wrapped bulbus fritillariae cirrhosae total alkaloids and platycodin D are efficiently introduced into cells. The inhaled pharmaceutical composition of the present invention collectively pushes macrophages from a pro-inflammatory M1 phenotype to a repairable M2 phenotype. Therefore, the overall curative effect of the combination of the two components is far better than that of the independent use of any component.

The invention discloses an imitated intercorial nano preparation for treating acute respiratory distress syndrome, and belongs to the technical field of biological medicine. The internalized nano preparation comprises an active component, a liposome phospholipid bilayer and a target head, wherein the active component consists of an ROS (reactive oxygen species) removing drug and an anti-inflammatory drug. According to the invention, efficient and accurate targeting of the nano-preparation is realized by innovatively applying an imitated interment effect, an apoptotic cell marker is modified on the surface of the liposome, and an'eat me 'signal is released to simulate a natural biological process that macrophages clear apoptotic cells to be recognized and swallowed by alveolar macrophages, so that efficient and specific targeting is realized, and the targeting effect of the nano-preparation is improved. Meanwhile, up-regulation of PS receptor expression of macrophages at the inflammation part further enhances the targeting effect, and a new way is provided for efficient delivery of acute respiratory distress syndrome medicine preparations and remodeling of pathological microenvironment.

The invention discloses a liposome targeting lung macrophages, the liposome is of a double-layer self-assembly structure, the particle size is more than 1 [mu] m, and the liposome comprises SPC, DOTAP, DSPE-PEG2000-mannose and cholesterol. The liposome has efficient targeting property, and the loaded Kdm6a mRNA can recover the expression of KDM6A in macrophages and inhibit the secretion of THBS1, so that the glycerophospholipid metabolism of ATII cells is repaired, the pulmonary fibrosis is improved, and the treatment effect is remarkable.

The application discloses a compound containing a 3-alkynyl pyrrole structure and application thereof. The compound containing the 3-alkynyl pyrrole structure provided by the application is confirmed to have a down-regulation effect on inflammatory factors secreted by LPS-induced primary alveolar macrophages through cell experiments, and has no obvious cytotoxicity. The application provides a new treatment strategy for clinical acute lung injury (ALI) treatment.

The invention discloses an application of resveratrol in preparation of a medicine for treating pulmonary ischemia reperfusion injury, relates to the technical field of biological medicines, and particularly relates to an application of resveratrol in preparation of a medicine for treating pulmonary ischemia reperfusion injury. The resveratrol is used for preparing the medicine for treating the pulmonary ischemia reperfusion injury, and the resveratrol in the medicine inhibits cell apoptosis by activating an RSPO3 / Wnt / beta-catenin signal channel, so that the pulmonary ischemia reperfusion injury is relieved; the resveratrol in the medicine can relieve the pulmonary ischemia reperfusion injury by inhibiting apoptosis of alveolar macrophages induced by hypoxia / reoxygenation; the conditions for inhibiting apoptosis induced by hypoxia / reoxygenation by adopting resveratrol are as follows: the resveratrol with the concentration of 2.5 mu M is adopted to pretreat macrophages; the resveratrol plays a protection role by activating an RSPO3 / Wnt / beta-catenin signal channel, and a new basis is provided for the medical application; the resveratrol is applied to preparation of the medicine for treating the lung ischemia-reperfusion injury, cell apoptosis is inhibited, and lung tissue injury is relieved.

The invention discloses a traditional Chinese medicine composition for treating allergic asthma and a preparation method thereof, and the traditional Chinese medicine composition comprises the following components in parts by weight: 2-10 parts of honey-fried ephedra, 3-10 parts of scutellaria baicalensis, 9-15 parts of momordica grosvenori, 9-15 parts of rhizoma dioscoreae nipponicae, 5-10 parts of scalded semen armeniacae amarae, 2-10 parts of liquorice, 3-10 parts of fried fructus perillae, 3-9 parts of fried semen brassicae, 5-10 parts of schizonepeta, 3-10 parts of platycodon grandiflorum and 5-12 parts of fried semen raphani. The pharmaceutical composition disclosed by the invention is a pure traditional Chinese medicine preparation, and can be used for reducing the level of eosinophilic granulocytes, increasing the number of alveolar macrophages and effectively improving abnormal immune response in an asthma process; lesion degrees such as lung tissue inflammatory cell infiltration, alveolar wall edema and goblet cell hyperplasia are relieved; secretion of Th2 type inflammatory cell related factors and IgE is reduced, and finally the effect of treating allergic asthma inflammatory response is achieved.

Disclosed are Schistosoma japonicum eggs and the ingredients of secretions and excretions thereof, comprising eggs, egg culture supernatant, and egg secreted proteins. (hereinafter referred to as “Schistosoma eggs and secretions and excretions thereof” for short). A Schistosoma infection can significantly inhibit metastatic tumors of organs such as lungs, and an anti-tumor effect is mediated by the “Schistosoma eggs and secretions and excretions thereof”, which have the effect of inhibiting various host tumors, comprising lung cancer, liver cancer, melanoma, and hematological tumors. Two egg secreted proteins having an anti-tumor effect are further identified. The “Schistosoma eggs and secretions and excretions thereof” exert an anti-tumor effect by activating natural immunity such as alveolar macrophages. The “Schistosoma eggs and secretions and excretions thereof” have a potential application value in prevention and treatment of tumors in humans.

The invention provides a monoclonal antibody for detecting pig source CD163 protein and a corresponding antigen epitope peptide. Wherein the hybridoma cell strain used for preparing the monoclonal antibody is CCTCC (China Center For Type Culture Collection) NO: C2025258. The monoclonal antibody provided by the invention is good in specificity, has good affinity with pCD163, and is clear in epitope information. The antibody can significantly inhibit the infection efficiency of PRRSV pedigree strains in alveolar macrophages, has a good PRRSV in-vitro blocking effect, can be used for developing a high-specificity pCD163 detection reagent, and is expected to be used as a candidate drug for passive immune prevention and treatment of PRRS.

The invention discloses a compound containing a 3-alkynyl pyrrole structure and application of the compound. Cell experiments prove that the compound containing the 3-alkynyl pyrrole structure provided by the invention has a down-regulation effect on inflammatory factors secreted by LPS-induced primary alveolar macrophages, and has no obvious cytotoxicity. According to the present invention, the new treatment strategy is provided for the clinical acute lung injury (Acute Lung Injury, ALI) treatment.

The invention relates to the technical field of biological medicines, and discloses an application of a targeted Sirt1 medicine for preventing lung injury caused by nanoparticles, primary alveolar macrophages are cultured in vitro, cells are stimulated by using single-walled carbon nanotubes, and changes of Sirt1 protein and mRNA (messenger ribonucleic acid) levels thereof are analyzed by using Western Blotting and RT-qPCR (real-time quantitative polymerase chain reaction) technologies, so that the targeted Sirt1 medicine for preventing lung injury caused by nanoparticles is obtained. Meanwhile, SA-beta-gal staining and p16 immunofluorescent staining are adopted for evaluating the aging state of the AMs, so that data of Sirt1 in AMs aging regulation and control are obtained; and regulating and controlling AMs aging data based on the obtained Sirt1. According to the application of the targeted Sirt1 medicine for preventing the lung injury caused by the nanoparticles, primary alveolar macrophages are cultured in vitro, single-walled carbon nanotubes are used for stimulating cells, Western Blotting and RT-qPCR technologies are used for analyzing Sirt1 protein and mRNA level changes of the Sirt1 protein, SA-beta-gal dyeing and p16 immunofluorescence dyeing are adopted for evaluating the aging state of AMs, and through a series of experiments, the targeted Sirt1 medicine for preventing the lung injury caused by the nanoparticles can be used for treating the lung injury caused by the nanoparticles. The specific mechanism of Sirt1 in AMs aging regulation and control can be determined, and solid basic data can be provided for subsequent drug development.

This invention provides a method for establishing a rat model of COPD to study the medicinal uses and pharmacological effects of Liuwei Buqi Decoction in the treatment of COPD. The traditional Chinese medicines in Liuwei Buqi Decoction are ginseng, astragalus, alpinia oxyphylla, polygonatum odoratum, tangerine peel, and cinnamon. This application provides a basis for the syndrome differentiation and treatment strategy of Liuwei Buqi Decoction by exploring the molecular mechanisms by which Liuwei Buqi Decoction regulates the COPD inflammatory immune network and the molecular mechanisms by which it regulates the lung-gut microecological axis and the inflammatory immune network. Taking the high-incidence syndromes of major diseases during the TCM-advantage stage as a starting point, and based on clinical needs, this study, building upon previous clinical research, uses various techniques such as scRNA-seq, CBA, and metagenomics to explore the molecular mechanism by which Liuwei Buqi Decoction improves airway immune inflammation by regulating the lung microecology in rats with COPD lung-kidney qi deficiency syndrome from the perspective of regulating the lung immune microenvironment and alveolar macrophage polarization. Its mechanism of action was further studied and verified through in vitro experiments.

The invention discloses application of an SLC39A1 specific regulating agent in preparation of a medicine for treating acute respiratory distress syndrome, and relates to the technical field of biological medicine. The medicine comprises an SLC39A1 specific regulating agent with a therapeutically effective amount and a pharmaceutically acceptable lung directional delivery carrier, the SLC39A1 specific regulating agent is selected from a group consisting of a nucleic acid molecule capable of specifically up-regulating the expression of an SLC39A1 gene, a small molecule compound capable of enhancing the zinc transport activity of the SLC39A1 protein and a recombinant protein; the lung directional delivery carrier is configured to deliver the SLC39A1 specific regulating agent to alveolar macrophages or lung microvascular endothelial cells in a targeted manner.

The present invention relates to a composition for use in the treatment of pulmonary fibrosis of a subject, wherein the composition comprises an inhibitor of miR-21 and a moiety that delivers said inhibitor of miR-21 to a macrophage. Further, the composition may be administered by a pulmonary administration. In particular aspects, said subject to be treated suffers from pulmonary fibrosis and further has a lung disease or disorder, wherein the lung disease or disorder may be a corona virus disease. Furthermore, the invention relates to a composition, wherein the composition comprises an inhibitor of miR-21 and a moiety that delivers said inhibitor of miR-21 to a lung macrophage.

The present invention relates to the fields of biology and medicine, and discloses the use of Dapansutrile (OLT1177) in the prevention and / or treatment of acute radiation-induced lung injury. The inventors of the present invention have found that Dapansutrile can prevent and / or treat acute radiation-induced lung injury in mice induced by local irradiation with ionizing radiation, including reducing the lung coefficient, alleviating pulmonary edema, inhibiting the aggregation of pulmonary macrophages, and reducing the secretion of serum inflammatory factors. Therefore, it can be used as a potential drug for the prevention and / or treatment of acute radiation-induced lung injury.

Circadian rhythms control the diurnal nature of many physiological, metabolic and immune processes. The inventors hypothesized that age-related impairments in circadian rhythms are associated with high susceptibility to bacterial respiratory tract infections. The diurnal control of Streptococcus pneumoniae infection is impaired in elderly mice. A lung circadian transcriptome analysis revealed that aging alters the daily oscillations in the expression of a specific set of genes and that some pathways that are rhythmic in young-adult mice are nonrhythmic or time-shifted in elderly mice. In particular, the circadian expression of the clock components Rev-erb-α, and Rev-erb-β to a lesser extent, altogether with apelin / apelin receptor were altered in elderly mice compared to young mice. In young mice, the inventors discovered that novel interaction between Rev-erb and the apelinergic axis controls host defenses against S. pneumoniae via alveolar macrophages. Pharmacological repression of Rev-erb-α and / or Rev- erb-β in elderly mice resulted in greater resistance to pneumococcal infection. Thus, the present invention relates to the use of Rev-erb antagonists for the treatment of lung infections.

The invention belongs to the technical field of medicine. The invention discloses an application of forsythiaside A in preparation of a medicine for treating bacterial infectious pneumonia. The method comprises the following steps: firstly, establishing a model of mice bacterial infectious pneumonia caused by tracheal intubation instillation of Pseudomonas aeruginosa in vivo, and applying forsythiaside A to treat, so that the infection symptom of the model mice can be obviously relieved, and the lung inflammatory response can be effectively relieved. The method comprises the following steps: firstly, establishing a model of pulmonary alveolar macrophages infected with Pseudomonas aeruginosa, Klebsiella pneumoniae or Acinetobacter baumannii in vitro, and then, establishing a model of pulmonary alveolar macrophages infected with Pseudomonas aeruginosa, Klebsiella pneumoniae or Acinetobacter baumannii in vitro, so that after forsythiaside A is added, the damage of the macrophages can be effectively alleviated, and the number of infectious bacteria in cytoplasm can be reduced. Experimental results show that forsythiaside A can be effectively used for treating bacterial infectious pneumonia.

A purpose of the present disclosure is to provide a method for testing presence / absence, severity or prognosis of pulmonary hypertension; a pathological model animal for pulmonary arterial hypertension; and a prophylactic or therapeutic drug for hypertension. Provided are: a testing method for hypertension, with Regnase-1 used as a biomarker; a PAH pathological model animal consisting of a non-human animal with Regnase-1 deficiency in alveolar macrophage; and a prophylactic or therapeutic drug for hypertension, containing a substance that disrupts a stem-loop structure in 3′UTR of Regnase-1 mRNA.

A method for generating progeny of an African swine fever (ASF) virus includes providing an isolated or purified fetal porcine lung alveolar macrophage cell capable of replicating the ASF virus, wherein the cell is cultured for at least 5 passages; exposing the cell to the ASF virus; and allowing the ASF virus to replicate in the cell; thereby generating progeny of the ASF virus.

Provided is use of lithium carbonate in the treatment of pulmonary fibrosis. In particular, provided is use of lithium carbonate or a pharmaceutical composition containing the same in the preparation of a drug for treating pulmonary fibrosis. Provided is a method for regulating the phenotype of alveolar macrophages in vitro. The method comprises the following steps: 1) acquiring alveolar macrophages; and 2) making the alveolar macrophages in contact with lithium carbonate or a pharmaceutical composition containing the same.

The invention discloses application of a dog alveolar macrophage exosome in treatment of canine fossa cough, and belongs to the technical field of veterinary biological products. The canine alveolar macrophage exosome is a cell exosome obtained by using canine bordetella bronchiseptica exotoxin to stimulate canine alveolar macrophages. Compared with the conventionally-cultured canine alveolar macrophage exosome, the secretion amount of the canine alveolar macrophage exosome can be remarkably increased by using the canine bordetella bronchiseptica exotoxin to stimulate the canine alveolar macrophage exosome. Both the conventional exosome and the canine bordetella bronchiseptica exotoxin-induced exosome with the same dosage can weaken the inhibition effect of the canine bordetella bronchiseptica exotoxin on the activity of canine lung fibroblasts, and the toxin-induced exosome has a better canine lung fibroblast damage repair effect than the conventional exosome. The toxin-induced exosome has a remarkable treatment effect on the canine nest cough, the death rate of the nest cough can be reduced, and the clinical attack time is shortened.

Method of treating secondary cancer in a lung of a subject in need thereof, comprising administering a pharmaceutical composition comprising an effective amount of an inhibitor of transcriptional enhanced associate domain (TEAD) to the subject. In addition, methods of inhibiting growth of a secondary tumor in a lung of a subject in need thereof, of increasing number of T-cells at a secondary tumor in a lung of a subject in need thereof, of increasing number of alveolar macrophages in a lung of a subject in need thereof, of decreasing number of infiltrating monocytes / macrophages in a lung of a subject in need thereof, methods of reducing lung metastases in a subject in need thereof, method of inducing polarization of one or more M2 macrophages to M1 macrophages in the lung of a subject with lung cancer, and methods of activating IL12 signaling in lung of a subject with lung cancer.

Provided herein are polypeptides including an amino acid sequence having at least 70% sequence identity with an Isthmin 1 (ISM1) protein or a GRP78-activating fragment thereof, as well as expressible nucleic acids encoding said polypeptides. Uses of such agents, as well as methods for inducing apoptosis in alveolar macrophages and / or for treating, ameliorating, or preventing inflammation or lung disease such as chronic obstructive pulmonary disease (COPD), emphysema, asthma, acute lung injury (ALI), lung fibrosis, and / or acute respiratory distress syndrome.

The invention discloses an active oxygen (ROS) response type targeted liposome double-drug co-delivery system for treating pulmonary fibrosis as well as a preparation method and application thereof, and belongs to the technical field of biological medicine and nano-drug delivery. Structural phospholipid, charged phospholipid, cholesterol and a polyethylene glycol-phospholipid derivative containing a thioketal bond and cRGD peptide are used as membrane materials, GC-1 is embedded into a phospholipid bilayer through a membrane hydration-extrusion method, salvianolic acid B is encapsulated in the liposome, and the liposome with negative electricity on the surface is prepared. Negative charges on the surface of the liposome are beneficial to penetrating an airway mucus barrier and reducing alveolar macrophage removal, the modified cRGD enables the liposome to be enriched in a fibrosis focus, and the thioketal bond fractured liposome rapidly disintegrates and releases drugs in a high ROS environment in a focus area. The synergistic treatment that GC-1 promotes alveolar epithelium type II cells to be redifferentiated into type I cells and salvianolic acid B removes ROS is achieved, and therefore the pulmonary fibrosis process is efficiently reversed.

The invention belongs to the technical field of medicines, and particularly relates to a nauclea officinalis-alpinia oxyphylla composition for regulating macrophage polarization and application thereof.The nauclea officinalis-alpinia oxyphylla composition is obtained by mixing nauclea officinalis and alpinia oxyphylla, adding water, heating and extracting, concentrating under reduced pressure and drying. The composition obtained by the invention can significantly reduce proinflammatory factors, improve anti-inflammatory factors and promote lung tissue repair by bidirectional regulation and control of alveolar macrophage polarization, and provides a new scheme for clinical treatment of acute lung injury.

The application discloses application of CD244 in a gene editing target point against African swine fever. The application provides application of a substance capable of inhibiting CD244 expression in preparation of a product for treating and / or preventing African swine fever virus infection. Inhibition of expression of the CD244 gene in porcine primary alveolar macrophage (PAM) can significantly interfere with ASFV replication, and overexpression of CD244 can significantly promote ASFV replication in an iPAM cell line. The application provides new materials for research and development of anti-ASFV infection drugs and pig disease-resistant breeding.

The invention belongs to the technical field of biological medicines, and particularly relates to acacetin-containing lipid nanoparticles for a pulmonary inhalation type mRNA vaccine as well as a preparation method and application of the acacetin-containing lipid nanoparticles. The lipid nano-particle takes acacetin as a functional fifth component, is jointly composed of ionized lipid, neutral auxiliary lipid, cholesterol and polyethylene glycol lipid, and can effectively wrap mRNA (messenger Ribonucleic Acid) of an encoding antigen. According to the preparation method, high-efficiency compounding of lipid and mRNA is realized through a microfluidic technology, the particle size of the obtained particles is adaptive to lung targeting, alveolar macrophage removal can be reduced, mRNA is protected from peroxidation damage, and vaccine response is enhanced through the immunomodulatory effect of acacetin. The system can be prepared into a lung inhalation type mRNA vaccine, is used for preventing and controlling respiratory tract infectious diseases, has high-efficiency delivery, strong immunization and good safety, and provides a new scheme for construction of a lung immune barrier.

The invention discloses an alveolar macrophage inhibitory natural product monomer and application thereof, and relates to the technical field of biological medicines. Seven natural product monomers including polyphyllin B, gentisic acid, catalpol, abscisic acid, aescin, ginsenoside and guaiacol are obtained through screening, and the menin / SETD2 interaction can be specifically inhibited. Experiments show that the monomers can inhibit expression of various inflammatory factors such as IL-1alpha, IL-1beta, IL-6 and the like induced by LPS in a dose-dependent manner; animal experiments prove that the monomers can obviously inhibit release of inflammatory factors induced by pathogens such as LPS and streptococcus pneumoniae, and can effectively relieve acute pneumonia and lung injury of mice. The provided natural product monomer is clear in target spot, specific in effect and broad in anti-inflammatory effect spectrum, and has important application prospects in treatment of cell / inflammatory factor storm related diseases caused by abnormal activation of alveolar macrophages.

The invention discloses application of a substance capable of up-regulating the KDM6A protein level in lung macrophages in preparation of a medicine for treating or preventing pulmonary fibrosis. The invention also discloses application of the KDM6A protein in the lung macrophage as a marker in preparation of a pulmonary fibrosis diagnosis or prediction kit. KDM6A is found to be an important signal molecule of a macrophage-epithelial cell metabolic pathway, and the expression of KDM6A in lung macrophages is recovered, and THBS1 secretion is inhibited, so that glycerophospholipid metabolism of ATII cells is repaired, and pulmonary fibrosis is improved.